Bionano Genomics, Inc. reports results for the quarter ended September 30 - Earnings Summary

• Bionano Genomics, Inc. reported a quarterly adjusted loss of 54 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of $-1.59. The mean expectation of two analysts for the quarter was for a loss of 49 cents per share. Wall Street expected results to range from -56 cents to -42 cents per share.

• Revenue rose 12.3% to $8.28 million from a year ago; analysts expected $8.44 million.

• Bionano Genomics, Inc.'s reported EPS for the quarter was a loss of 54 cents​.

• The company reported a quarterly loss of $6.45 million.

• Bionano Genomics, Inc. shares had fallen by 25.6% this quarter and lost 24.2% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts was unchanged in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the advanced medical equipment & technology peer group is also "buy"

• Wall Street's median 12-month price target for Bionano Genomics, Inc. is $5.00, about 76.8% above its last closing price of $1.16

This summary was machine generated from LSEG data November 10 at 10:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)